Evelo Biosciences & Jameel Health Announce Strategic Collaboration
March 26, 2021 | Source: YAHOO! Finance
Yahoo-Finance-logo
YAHOO! Finance reports on a strategic collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 to people in select developing markets as Jameel Health’s first biotechnology licensing agreement.
“We are honored to be selected as Jameel Health’s first therapeutic biotech collaborator,”
Simba Gill, Ph.D., Chief Executive Officer of Evelo.
Read the full article in its original location here.
Related Articles
Arab Health: Early screening 'best weapon' in fight against cancer
An article by The National magazine highlights the latest healthcare technologies presented by Abdul Latif Jameel Health at Arab Health 2023.
Read more
Healthtech provider targets early cancer detection across MENA
Arabian Gulf Business Insight had a conversation with Dr. Akram Bouchenaki, CEO of Abdul Latif Jameel Health, discussing the company's presence in the Global South and the cutting-edge technology it brings to the region.
Read more
One-stop shop helping revolutionize Mideast’s healthcare sector
Arab News engaged in a discussion with Dr. Akram Bouchenaki, CEO of Abdul Latif Jameel Health, to explore the ways in which the company is fulfilling its mission to accelerate modern innovation and deliver advanced healthcare solutions to individuals who might otherwise lack access to them.
Read more
Podcast looks to the future of innovation in the global health sector
Latest Healthark Insights podcast looks to the future of innovation in the global health sector
Read more
Evelo Biosciences Says Co. & Jameel Health Entered Strategic Collaboration
Reuters reports that Evelo Biosciences and Jameel Health enter a strategic collaboration.
Read moreFor press inquiries click here, or call +971 4 448 0906 (GMT +4 hours UAE). For public inquiries click here.
